SCH 79797 dihydrochloride - CAS 1216720-69-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C23H25N5.2HCl
Molecular Weight:
444.41
COA:
Inquire
Targets:
Protease-Activated Receptors (PARs)
Description:
SCH 79797 dihydrochloride is a potent and selective non-peptide PAR1 receptor antagonist (IC50 = 70 nM). SCH 79797 blocks haTRAP-induced human platelet aggregation. It also inhibits PAR1 agonist- or thrombin-induced increases in cytosolic Ca2+ in vascular smooth muscle cells.
Brife Description:
PAR1 receptor antagonist
Purity:
≥99% by HPLC
Synonyms:
N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine dihydrochloride
MSDS:
Inquire
InChIKey:
NNJTXSQXGHYXAJ-UHFFFAOYSA-N
InChI:
InChI=1S/C23H25N5.2ClH/c1-14(2)16-5-3-15(4-6-16)13-28-12-11-18-20(28)10-9-19-21(18)22(24)27-23(26-19)25-17-7-8-17;;/h3-6,9-12,14,17H,7-8,13H2,1-2H3,(H3,24,25,26,27);2*1H
Canonical SMILES:
CC(C)C1=CC=C(C=C1)CN2C=CC3=C2C=CC4=C3C(=NC(=N4)NC5CC5)N.Cl.Cl
1.SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
Strande JL;Hsu A;Su J;Fu X;Gross GJ;Baker JE Basic Res Cardiol. 2007 Jul;102(4):350-8. Epub 2007 Apr 30.
Myocardial ischemia/reperfusion (I/R) injury is partly mediated by thrombin. In support, the functional inhibition of thrombin has been shown to decrease infarct size after I/R. Several cellular responses to thrombin are mediated by a G-protein coupled protease-activated receptor 1 (PAR1).However, the role of PAR1 in myocardial I/R injury has not been well characterized. Therefore, we hypothesized that PAR1 inhibition will reduce the amount of myocardial I/R injury. After we detected the presence of PAR1 mRNA and protein in the rat heart by RT-PCR and immunoblot analysis,we assessed the potential protective role of SCH 79797, a selective PAR1 antagonist, in two rat models of myocardial I/R injury. SCH 79797 treatment immediately before or during ischemia reduced myocardial necrosis following I/R in the intact rat heart. This response was dose-dependent with the optimal dose being 25 microg/kg IV. Likewise, SCH 79797 treatment before ischemia in the isolated heart model reduced infarct size and increased ventricular recovery following I/R in the isolated heart model with an optimal concentration of 1 microM. This reduction was abolished by a PAR1 selective agonist. SCH 79797-induced resistance to myocardial ischemia was abolished by wortmannin, an inhibitor of PI3 kinase; L-NMA, a NOS inhibitor; and glibenclamide, a nonselective K(ATP) channel blocker.
2.Induction of tumor necrosis factor (TNF) release from subtypes of T cells by agonists of proteinase activated receptors.
Yang H;Li T;Wei J;Zhang H;He S Mediators Inflamm. 2013;2013:165453. doi: 10.1155/2013/165453. Epub 2013 Dec 16.
Serine proteinases have been recognized as playing an important role in inflammation via proteinase activated receptors (PARs). However, little is known about the influence of serine proteinases and PARs on TNF secretion from highly purified T cells. We challenged T cells from human peripheral blood with serine proteinases and agonist peptides of PARs and measured the levels of TNF in culture supernatants by ELISA. The results showed that thrombin and trypsin, but not tryptase, stimulated approximately up to 2.5-fold increase in TNF release from T cells following 16 h incubation. Proteinase inhibitors and PAR-1 antagonist SCH 79797 almost completely abolished thrombin- and trypsin-induced TNF release from T cells. Agonist peptides of PAR-1, but not PAR-2 induced TNF release from T cells. Moreover, trypsin- and thrombin-induced upregulated expression of TNF was observed in CD4+, IL-4+, or CD25+ T cells, but not in IFN+ or IL-17+ T cells. The signaling pathways MAPK/ERK and PI3K/Akt are involved in the thrombin- and trypsin-induced TNF release from T cells. In conclusion, thrombin and trypsin can induce TNF release from IL-4+ and CD25+ T cells through activation of PAR-1 and therefore contribute to regulation of immune response and inflammation of the body.
3.Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration.
Popovic M;Laumonnier Y;Burysek L;Syrovets T;Simmet T J Leukoc Biol. 2008 Jul;84(1):215-23. doi: 10.1189/jlb.0907652. Epub 2008 Apr 24.
CX3CL1 (fractalkine, neurotactin) is the sole CX3C chemokine. It induces monocyte locomotion in its cleaved form, but in its membrane-anchored form, it also acts as an adhesion molecule. The expression of CX3CL1 is up-regulated in endothelial cells by proinflammatory cytokines such as IL-1 or TNF-alpha. Here, we studied the effect of the serine protease thrombin on endothelial CX3CL1 induction and its putative relevance for monocyte function. In HUVEC, thrombin triggered a time- and concentration-dependent expression of CX3CL1 at the mRNA and the protein level as shown by RT-PCR, Western immunoblotting, and flow cytometric analysis. Thrombin induced CX3CL1 by activating protease-activated receptor 1 (PAR1) as demonstrated by the use of PAR1-activating peptide and the PAR1-specific antagonist SCH 79797. The thrombin-induced CX3CL1 expression was NF-kappaB-dependent, as shown by EMSA, ELISA, and by inhibition of the NF-kappaB signaling pathway by the IkappaB kinase inhibitor acety-11-keto-beta-boswellic acid or by transient overexpression of a transdominant-negative form of IkappaBalpha. Upon cocultivation of human monocytes with HUVEC, the thrombin-dependent induction of membrane-anchored CX3CL1 in HUVEC triggered monocyte adhesion and an enhanced release of the MCP-1/CCL2 by monocytes and potentiated the monocyte transendothelial migration.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Protease-Activated Receptors (PARs) Products


Atopaxar
(CAS: 751475-53-3)

Atopaxar is a Protease-activated receptor-1 (PAR-1) inhibitor. It can inhibit the binding of a high-affinity thrombin receptor-activating peptide ([(3)H]haTRAP)...

CAS 729589-58-6 2-Furoyl-LIGRLO-amide

2-Furoyl-LIGRLO-amide
(CAS: 729589-58-6)

2-Furoyl-LIGRLO-amide is a potent and selective PAR2 receptor agonist (pD2 = 7.0). It causes a dose-dependent relaxation of murine femoral arteries.

CAS 171436-38-7 SLIGRL-NH

SLIGRL-NH
(CAS: 171436-38-7)

LIGRL-NH2 is a PAR2 activator with EC50 value of ~5 µM. It can be used to explore signaling through PAR2 in cells.

BMS-986120
(CAS: 1478712-37-6)

BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vasc...

CAS 1216720-69-2 SCH 79797 dihydrochloride

SCH 79797 dihydrochloride
(CAS: 1216720-69-2)

SCH 79797 dihydrochloride is a potent and selective non-peptide PAR1 receptor antagonist (IC50 = 70 nM). SCH 79797 blocks haTRAP-induced human platelet aggregat...

CAS 1051487-82-1 AC 264613

AC 264613
(CAS: 1051487-82-1)

AC 264613 is a potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5). AC 264613 inhibits interferon regulatory factor 5 and decreases ...

CAS 190383-13-2 SLIGKV-NH2

SLIGKV-NH2
(CAS: 190383-13-2)

SLIGKV-NH2 is a protease-activated receptor 2 (PAR2) agonist (Ki = 9.64 μM; IC50 = 10.4 μM).

CAS 916170-19-9 AC-55541

AC-55541
(CAS: 916170-19-9)

AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist which displays no activity at other PAR subtypes or at over 30 other receptors in...

CAS 474550-69-1 E 5555 hydrobromide

E 5555 hydrobromide
(CAS: 474550-69-1)

E 5555 hydrobromide is a potent and orally bioactive thrombin receptor (or protease-activated receptor 1, PAR1) antagonist (IC50 = 19 nM). It inhibits human pla...

CAS 89159-60-4 ML 354

ML 354
(CAS: 89159-60-4)

ML 354 is a selective PAR4 antagonist with IC50 value of 140 nM.

CAS 173904-50-2 FR 171113

FR 171113
(CAS: 173904-50-2)

FR 171113 is a protease-activated receptor 1 (PAR1) antagonist displaying significant antiplatelet activity in vitro. It inhibits thrombin TRAP-6-induced platel...

CAS 141136-83-6 Thrombin Receptor Activator Peptide 6

Thrombin Receptor Activator Peptide 6
(CAS: 141136-83-6)

TRAP-6, a peptide compound, has been found to be a PAR1 agonist and could also influence the phosphorylation of rapid phosphodiesterase 3A in the positive way.

CAS 1252806-86-2 GB 83

GB 83
(CAS: 1252806-86-2)

GB 83 is a selective antagonist of human protease activated receptor 2 (PAR2) (IC50 = 2 mM).

CAS 245329-02-6 FSLLRY-NH2

FSLLRY-NH2
(CAS: 245329-02-6)

FSLLRY-NH2 is a selective PAR2 peptide antagonist. It reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice, also suppre...

BMS-986141

BMS-986141 is a dual antagonist of proteinase-activated receptor 1 (PAR1) and PAR4. BMS-986141 was confirmed in cynomolgus monkeys to be a better therapy for pr...

CAS 245329-01-5 LRGILS-NH

LRGILS-NH
(CAS: 245329-01-5)

LRGILS-NH is a control peptide for SLIGRL-NH2, a protease-activated receptor-2 (PAR2) agonist that facilitates gastrointestinal transit in vivo.

UDM-002555

UDM-002555 is a small-molecule and selective antagonist of protease-activated receptor-4 (PAR-4). It can suppress the activation of platelet in dose manner. In ...

CAS 618385-01-6 Vorapaxar

Vorapaxar
(CAS: 618385-01-6)

SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently un...

CAS 327177-34-4 tcY-NH2

tcY-NH2
(CAS: 327177-34-4)

tcY-NH2 is a selective PAR4 antagonist peptide that inhibits aggregation caused by receptor-activating peptide analogs (GY-NH2, AY-NH2) and thrombin.

CAS 942413-05-0 VKGILS-NH2

VKGILS-NH2
(CAS: 942413-05-0)

VKGILS-NH2 is a reversed control peptide for SLIGKV-NH2, which is a protease-activated receptor 2 (PAR2) agonist.

Chemical Structure

CAS 1216720-69-2 SCH 79797 dihydrochloride

Quick Inquiry

Verification code

Featured Items